A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE)
*The trial information contained on this page was imported from ClinicalTrials.gov. Click here to view this trial on ClinicalTrials.gov.
- Full Title:
- A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
- Myeloma stage or condition:
- Myeloma Myeloma Multiple
- Study phase:
- Phase 2
- Summary/Purpose:
- This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
- Detailed Description:
- Chemotherapy for malignancies is predominantly prescribed and delivered in a tertiary hospital and/or cancer centre setting. However, with modern chemotherapy, with a reduced side effect profile, this paradigm should be challenged. Indeed, the use of methotrexate and other biologics (a form of chemotherapy) in the Rheumatologic setting is commonly delivered effectively and safely in the community. Taken together, a hospital-based model of chemotherapy delivery may not be warranted in all circumstances. Moreover, the use of this current model invariably discounts the time commitments, needs of patients and caregivers, as well as while not addressing the emerging concerns regarding system capacity, efficiency and effectiveness of safe chemotherapy delivery.
- Treatments:
- Drug : Bortezomib Injection
Subcutaneous injection
- Study Arms:
- Other : Self Injection of Bortezomib
Subcutaneous self administration of bortezomib
- Study Type:
- Interventional
- Study Design:
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Recruitment status:
- Recruiting
- Eligibility criteria:
-
Inclusion Criteria:
- Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,
- Stable clinical status as deemed by responsible investigator,
- Personally (or caregiver) willing and deemed capable to self-administer with teaching,
- Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment,
- Signed informed consent.
- Currently participating in clinical trials that includes the use of bortezomib,
- History of allergic reactions to bortezomib,
- History of bleeding attributable to bortezomib,
- History of greater than or equal to grade 3 side effects attributable to bortezomib,
- Clinically deemed unlikely to be compliant with therapy by responsible investigator,
- Life expectancy anticipated to be less than 6 months,
- Deemed geographically inaccessible to receive care.
- Locations / Centres:
-
Tom Baker Cancer Centre, Calgary, Alberta – Recruiting
- Contacts:
- Name: Jason Tay, MD
Phone: 403-944-3265
Email: [email protected]
- Publications:
- ???
- First posted:
- 2020-02-13
- Actual start date:
- May 29, 2020
- Last updated:
- 2023-10-12
- Estimated enrollment:
- 100
- Estimated completion date:
- 2026-05-01
- Estimated primary completion date:
- 2024-05-01
- Condition:
- Myeloma
- Myeloma Multiple
- Gender:
- All
- Ages:
- 18 Years-N/A
- Accepts healthy volunteers:
- No
- Listed location countries:
- Canada
- NCT number:
- NCT04268199
- Other study ID numbers:
- EASE
- Has Data monitoring committee:
- Yes
- U.S. FDA-regulated product:
- No
- IPD Sharing Statement :
- ???
- Responsible party:
-
Sponsor
- Study sponsor:
- collaborator
Tom Baker Cancer Centre
Other - lead_sponsor
AHS Cancer Control Alberta
Other
- Collaborators:
- ???
- Investigators:
- Jason Tay, MD Tom Baker Cancer Centre
- Protocol Registration and Results System:
- ???
- Verification date:
- 2023-10-01